Fulltext

Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis

Distler, J. H. W. ; Distler, O.

In: Rheumatology, 2008, vol. 47, p. v10-v11

Ajouter à la liste personnelle
    Titre
    • Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis
    Auteur
    • Distler, J. H. W.. Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany and Department of Rheumatology, Center of Experimental Rheumatology and Center of Integrative Human Physiology, University Hospital Zurich, Zurich, Switzerland.
    • Distler, O.. Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany and Department of Rheumatology, Center of Experimental Rheumatology and Center of Integrative Human Physiology, University Hospital Zurich, Zurich, Switzerland.
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:303800
    Summary
    Tissue fibrosis is a major cause of death in SSc, but therapies that target selectively fibrosis are not yet available for routine clinical use. Recent pre-clinical studies suggest that selective tyrosine kinase inhibitors that target c-Abl, PDGF receptor or Src kinases might be promising targets for anti-fibrotic approaches. Dual inhibition of c-Abl and PDGF receptor by imatinib and nilotinib, and inhibition of Src kinases either selectively by SU6656 or in combination with c-Abl and PDGF by dasatinib exerted potent anti-fibrotic effects. Imatinib, nilotinib, dasatinib and SU6656 reduced dose-dependently the synthesis of extracellular matrix protein in human dermal fibroblasts in vitro and prevented fibrosis in the mouse model of bleomycin-induced skin fibrosis. Clinical data from patients with chronic myelogenous leukaemia suggest that imatinib, nilotinib and dasatinib are well tolerated. Based on the promising pre-clinical data, imatinib is currently evaluated in clinical trials for the treatment of fibrosis in SSc and trials with other tyrosine kinase inhibitors are in preparation